Education
About Us
Working with TipRanks
Follow Us
Lipocine Inc (LPCN)
NASDAQ:LPCN
LPCN Stock Chart & Stats
$2.92
-$0.05(-1.04%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.04%)
Day’s Range― - ―
52-Week Range$2.52 - $8.35
Previous CloseN/A
Volume16.76K
Average Volume (3M)69.37K
Market Cap
$41.81M
Enterprise Value$296.40K
Total Cash (Recent Filing)$15.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Mar 05, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding5,551,931
10 Day Avg. Volume103,401
30 Day Avg. Volume69,372
Financial Highlights & Ratios
PEG Ratio-31.18
Price to Book (P/B)1.24
Price to Sales (P/S)2.33
P/FCF Ratio-19.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.07
Enterprise Value/Gross Profit0.14
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$6.88Price Target Upside135.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe Phase 3 trial of LPCN 1154 in postpartum depression is on track to report topline data, which could lead to a new drug application submission in the U.S.
Efficacy And SafetyLipocine's LPCN 1154 improves the efficacy and safety profile compared to other treatments, with a rapid onset of action and no adverse events in trials.
Market PotentialLPCN 1154 has the potential to become the best-in-class neuroactive steroid that could satisfy unmet needs in postpartum depression.
Bears Say
Financial NeedsThe company may choose to raise additional capital within the next 12 months, indicating potential financial needs.
Financial PerformanceNet loss was $2.2M, or ($0.41) per share, in line with the estimated loss.
Lipocine News
LPCN FAQ
What was Lipocine Inc’s price range in the past 12 months?
Lipocine Inc lowest stock price was $2.52 and its highest was $8.35 in the past 12 months.
What is Lipocine Inc’s market cap?
Lipocine Inc’s market cap is $41.81M.
When is Lipocine Inc’s upcoming earnings report date?
Lipocine Inc’s upcoming earnings report date is Mar 05, 2026 which is in 52 days.
How were Lipocine Inc’s earnings last quarter?
Lipocine Inc released its earnings results on Nov 06, 2025. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.54 by -$0.05.
Is Lipocine Inc overvalued?
According to Wall Street analysts Lipocine Inc’s price is currently Undervalued.
Does Lipocine Inc pay dividends?
Lipocine Inc does not currently pay dividends.
What is Lipocine Inc’s EPS estimate?
Lipocine Inc’s EPS estimate is -0.61.
How many shares outstanding does Lipocine Inc have?
Lipocine Inc has 5,551,931 shares outstanding.
What happened to Lipocine Inc’s price movement after its last earnings report?
Lipocine Inc reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.54. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Lipocine Inc?
Currently, no hedge funds are holding shares in LPCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
LPCN Stock 12 Month Forecast
Average Price Target
$6.88
▲(135.45% Upside)
Technical Analysis
Ownership Overview
15.31%
Insiders
4.49% Mutual Funds
<0.01% Other Institutional Investors
76.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---